Navigation Links
European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri™
Date:2/17/2012

Coiffier, M.D., Ph.D., Professor of Hematology at the Department of Hematology, Hospices Civils de Lyon and the University Lyon 1 in Lyon, France.  

Similar to accelerated approval regulations in the United States, conditional marketing authorizations are granted to medicinal products with a positive benefit/risk assessment that address unmet medical needs and whose availability would result in a significant public health benefit. A conditional marketing authorization is renewable annually. Under the provisions of the conditional marketing authorization for Pixuvri, CTI will be required to complete a post-marketing study aimed at confirming the clinical benefit previously observed.

The CHMP has accepted PIX306, CTI's ongoing randomized controlled phase 3 clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in 2nd line patients with aggressive B‑cell NHL who failed front-line CHOP-R and who are not eligible for autologous stem cell transplant ("ASCT") or as 3rd or 4th line therapy in aggressive B-cell NHL. As a condition of approval, CTI has agreed to have available the PIX306 clinical trial results by June 2015.

For more information visit the EMA website at http://www.ema.europa.eu.

About Non-Hodgkin Lymphoma

NHL is caused by the abnormal proliferation of lymphocytes, cells key to the functioning of the immune system. It usually originates in lymph nodes and spreads through the lymphatic system. NHL can be broadly classified into two main forms—aggressive NHL is a rapidly growing form of the disease that moves into advanced stages much faster than indolent NHL, which progresses more slowly. The World Health Organization's International Agency for Research on Cancer's 2008 GLOBOCAN database most recent estimates state that in European Union approximately 74,162 people will be diagnosed with NHL and 31,371 are estimated to die from NHL e
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology
2. Intellect Neurosciences Submits Statement Setting Grounds for Appeal in European Patent Proceedings
3. European Pharmaceutical and Biotech Contract Manufacturing Markets
4. Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera® Marketing Authorisation and Requests Further Information From the CHMP
5. ULURU Inc. Extends the European Altrazeal® License to Include the Middle East and Africa
6. Kinex Pharmaceuticals Acquires Rights for Technology and Products from Hanmi Pharmaceuticals, in United States and European Union Territories
7. BioMarin Receives Positive Opinion from European Regulatory Authorities for Expanded Biologics Manufacturing Facility
8. Dehaier Medical Enters European Homecare Medical Product Market
9. Successful ILM-Blue Patent Opposition Proceedings Before the European Patent Office; Patent Validity Confirmed
10. No European Scientists Left by 2020?
11. US and European Bariatric (Obesity) Surgical Devices Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Mass. , Feb. 27, 2015  Boston Scientific ... participate in the Barclays 2015 Annual Healthcare Conference on ... Dan Brennan , executive vice president ... vice president, Investor Relations, will participate in a 25-minute ... host analyst at approximately 1:05 p.m. ET. Following a ...
(Date:2/27/2015)... Feb. 27, 2015   Synageva BioPharma Corp. ... company developing therapeutic products for rare diseases, joins ... European Organisation for Rare Diseases™ (EURORDIS™), The Global ... observing Rare Disease Day. On the ... industry, and other participants conduct special events to ...
(Date:2/27/2015)... /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: ... results for its first quarter ended December 31, 2014. ... 31, 2014, revenue was $1,336,685. Operating expenses were $1,063,393. ... per share.  Covalon,s President and CEO, ... with the significant progress we have made over the ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
... part of the brain first,affected by Alzheimers disease ... a risk gene for the disorder, a brain,imaging ... Mental,Health (NIMH), one of the National Institutes of ... structure in the lower middle,part of the brains ...
... 25, 2007 - Reata,Pharmaceuticals, Inc. today announced ... company's Synthetic Triterpenoid programs in,the May 2007 ... The article, "Triterpenoids and rexinoids as multifunctional,agents ... by researchers,and Reata scientific collaborators from the ...
Cached Medicine Technology:Cortex Area Thinner in Youth with Alzheimers-Related Gene 2Cortex Area Thinner in Youth with Alzheimers-Related Gene 3Cortex Area Thinner in Youth with Alzheimers-Related Gene 4Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 2Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 3Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 4
(Date:2/28/2015)... (PRWEB) February 28, 2015 The MCA ... across Malaysia into one platform and gears towards the ... , A series of group talks in smaller groups ... Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, Social ... raise awareness of Malaysian youths. , Young ...
(Date:2/28/2015)... 2015 With their commitment to achieving ... an additional exercise to their already robust library of ... most commonly known as, is often performed on a ... executed in a relatively safe manner and can be ... The full description of “Rope Pulls” is located in ...
(Date:2/28/2015)... BC (PRWEB) February 28, 2015 Vancouver personal ... personal injury claims are affected by time limits. They stated ... weaken a person’s claim or even nullify it. Many a ... effects on a client’s rights under BC law. As a ... are affected by accidents should consult a personal injury lawyer ...
(Date:2/28/2015)... Pioneer Millworks reclaimed USA wood will ... Construction Materials Show, an annual, premier sustainable building event ... and top manufacturers of the latest building products, services ... sourced and manufactured by Pioneer Millworks from their Oregon ... at restaurants, hotels, retailers, and corporate offices. Nichibi ...
(Date:2/28/2015)... Kaylie Corrigan, Outdoor Supervisor at ... and current student obtaining her Masters degree in social ... forum in psychoeducation on substance use for teens at ... part of her studies. , “Even though these students ... counseling at the high school and junior high school ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2
... a stroke could run a further risk of further strokes ... a new study. Recurrent// strokes could also disable nearly 50% ... the University at Chicago said” Stroke incidence and mortality are ... of this risk may be explained by a greater vascular ...
... cases of E. coli have been confirmed in Wisconsin, ... been caused by bagged spinach. One person has ... ,Governor Doyle said that 15 of the 30 ... are battling severe infection. Majority of the patients are ...
... chronic disease – myositis -- will speak to congressional staff ... the staff// hearing them on this day – designated 'Myositis ... this little-known and poorly understood disease. Internationally-known male model and ... personal friend, who is prominent in Europe and has the ...
... ever-rising obesity rates all over the world sparking many lifestyle ... just be what the doctor ordered. A pill// is soon ... risk. A mere consumption of the pill once or twice ... better glucose management, thus offsetting diabetes. ,The ...
... study at the Mayo Clinic has found that injecting an ... ,Men with abnormal digital rectal exams or elevated ... usually get prostate biopsies done. ,Nearly 16% pf the patients ... biopsy, according to a new study presented at the annual ...
... 42nd Annual Meeting of the European Association for the ... HCl), an oral// antidiabetic medication, demonstrated significant cardiovascular benefits ... C and acute coronary syndrome in patients with type ... leading cause of premature death in patients with diabetes. ...
Cached Medicine News:Health News:ACTOS Linked to Several Cardiovascular Benefits 2Health News:ACTOS Linked to Several Cardiovascular Benefits 3Health News:ACTOS Linked to Several Cardiovascular Benefits 4
... The EXOGEN 2000+ device provides a ... nonunion or the acceleration of fresh ... home for 20 minutes daily, or ... your physician determines your fracture to ...
Guardsman Femoral Interference Screw is specifically designed for endoscopic femoral fixation where graft protection is needed....
... Interference Screw is indicated for graft ... and PCL reconstructions with bone-patellar tendon-bone ... The SmartScrew ACL provides easy and ... for any graft type. The unique ...
... the TrueView II design, a new generation ... small joint arthroscopy is available. The new ... durable thanks to Olympus advanced fibre technology. ... means bright images, brilliant colour reproduction, high ...
Medicine Products: